Microfluidic nanotechnology for bioanalytical determination of nucleic acid molecules and medicinal compounds

对自然生长的植物，如大麻(或大麻)物种进行生物分析测定，将产生关于鉴定适当物种DNA以及提取和定量适当药物化合物的知识。目前的知识差距是找出从适当的植物物种中获得的适当数量的此类化合物，这些化合物将产生适当的靶向药物和迷幻效果。例如，印度大麻可能含有比花椰菜更有益的大麻二酚(CBD)。知识鸿沟将通过使用创新的微流控纳米技术来解决。他说，微流控纳米技术研究计划的长期目标是识别/确认适当的大麻物种，并检测/量化其适当的药用化合物。他说，未来五年的短期目标包括核酸测试和化学分析。在核酸测试方面，一般的技术将是利用创新的微流控芯片进行低流量液体流动的植物样本扩增测试，以及通过金纳米粒子进行分子或DNA检测。这种微流控生物技术使分子检测成为可能，从而使检测试剂盒价格低廉，便于现场使用。对于药物化合物的化学分析，通常的方法是分析分离，如毛细管电泳法。利用创新的微流控纳米技术，我们将整合样品提取和分析分离，使药物化合物能够快速和准确地定量。因此，我们首次获得了基于合成生物活性化合物的酶的编码基因检测DNA的初步数据。预期的结果是确定大麻物种的核酸，并对CBD等植物大麻素进行量化。由于农业需求和防止欺诈，这种分子分析变得越来越重要。我们首次通过传统的分析分离方法对大麻中的药物化合物进行了量化。我们希望通过将上游提取与下游微流控分析分离相结合，获得更准确的量化数据。最近，由于药物滥用预防和法律执行需要检测试剂盒，这种检测方法变得越来越重要。为了达到预期的效果，测试套件的低成本和便携性对于现场的加拿大最终用户来说尤其重要，只需最少的培训。例如，对于土著社区来说，检测试剂盒是用户友好的；他们可以通过更好的控制在现场分析他们的植物样本，而不是在他们无法进行交叉检查的远程实验室中分析。在集成的微流控系统中进行分析时，植物样品中大麻类化合物的生物分析测定更准确。

Bioanalytical determinations conducted on naturally occurring plants, such as Cannabis (or marijuana) species, will generate knowledge on the identification of the proper species DNA, and on the extraction and quantitation of appropriate medicinal compounds.     The current knowledge gap is to find out appropriate amounts of such compounds obtained from the proper plant species that will generate suitable targeted medicinal and psychedelic effects. For instance, C. indica may consist of more beneficial cannabidiol (CBD) than C. sativa does. The knowledge gap is to be handled by the use of the innovative microfluidic nanotechnology.     The long-term goal of the microfluidic nanotechnology research program is to identify/confirm the proper Cannabis species and detect/quantify their appropriate medicinal compounds.     The short-term objectives over the next five years include nucleic acid testing, and chemical analysis. For nucleic acid testing, the general technique will be amplification tests achieved on plant samples by innovative microfluidic chips for low-volume liquid flow and by gold nanoparticles for molecular or DNA detection. This microfluidic biotechnology enables the molecular testing in order to make the test kits inexpensive and portable for field uses. For chemical analysis of medicinal compounds, the general approach is analytical separations, such as capillary electrophoresis. Using innovative microfluidic nanotechnology, we will integrate sample extraction and analytical separation that enables fast and accurate quantification of medicinal compounds.     For the first time, we obtain preliminary data on detecting DNA based on the coding gene for the enzyme that synthesizes the bioactive compounds. The expected outcomes are to identify the nucleic acids of the Cannabis species and to quantify the plant cannabinoids, such as CBD. Such molecular assays become increasingly important because of agricultural needs and fraud prevention. We are first on quantifying the medicinal compounds in cannabis by conventional analytical separations. We expect to obtain more accurate quantification data enabled by integrating upstream extraction with the microfluidic analytical separation downstream. Such assays are gaining importance recently because of the need of test kits for substance abuse prevention and legal enforcement.     For anticipated impact, the low-cost and portability of test kits are particularly important features for Canadian end users on-site with minimal training. For instance, for the indigenous communities, the test kits are user-friendly; they can analyze their plant samples on-site with a better control, rather than in remote labs that are out of their reach for cross-examinations. The bioanalytical determinations of cannabinoids in plant samples are more accurate when analyzed in the integrated microfluidic system.